SS Innovations International, Inc. announced the successful completion of 500 robotic surgeries using the Company's innovative SSi Mantra Surgical Robotic System, and marking another significant milestone for the Company. Dr. Sudhir K. Rawal, Medical Director and Chief of the Urology-Oncology Department at the Rajiv Gandhi Cancer Institute and Research Center in New Delhi, was proud that it was his team that achieved this significant milestone by successfully completing the 500th procedure using the SSi Mantra S surgical Robotic System. He was assisted by Dr. Amitabh Singh, a renowned surgeon in the field of Urology Oncology and a distinguished surgeon from Dr. Rawal's team.

This recognition is noteworthy given Dr. Rawal and the Rajiv Gandhi Cancer Institutes' help in securing SS Innovations' clinical validation, but also as the first healthcare institution in the Indian Subcontinent to acquire the system, and as a result, performing the volume of clinical procedures with the SSi Mantra Robotic System within all of India to date. After crossing the significant milestone mark, the 501st surgery was performed by SS Innovations International Inc., Founder and Chairman, Dr. Sudhir P. Srivastava, and was a bilateral internal mammary artery takedown procedure to be utilized in a heart surgery patient with significant coronary artery disease. The two harvested internal mammary arteries were used to bypass blocked coronary arteries, restoring blood flow to previously disease areas of the heart, and resulting in improved functioning of the heart.

Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra SurgicalRobotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular arm configuration, 3D 4K vision open-console design and superior ergonomics, the system engages with the surgeon and surgical teams to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 40 different types of surgical procedures.

The company expects to seek regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe in 2024 and 2025.